Option Care Health (NASDAQ:OPCH) Coverage Initiated at TD Cowen

Key Points

• TD Cowen has initiated coverage of Option Care Health (NASDAQ: OPCH) with a "hold" rating and set a price target of $30.00, suggesting a potential upside of 10.13% from the previous close.
• The company reported $1.42 billion in revenue for its last quarter, exceeding analysts' expectations, and achieved an earnings per share of $0.41, up from $0.30 in the same quarter last year.
• Institutional investors own approximately 98.05% of Option Care Health's stock, indicating strong institutional backing and confidence in the company's future performance.

Equities research analysts at TD Cowen initiated coverage on shares of Option Care Health (NASDAQ:OPCH - Get Free Report) in a research report issued to clients and investors on Thursday,Briefing.com Automated Import reports. The firm set a "hold" rating and a $30.00 price target on the stock. TD Cowen's price objective would suggest a potential upside of 10.13% from the company's previous close.

OPCH has been the subject of several other research reports. Citigroup restated an "outperform" rating on shares of Option Care Health in a research note on Thursday, July 31st. Cowen started coverage on Option Care Health in a research report on Thursday. They issued a "hold" rating on the stock. JMP Securities upped their price target on shares of Option Care Health from $36.00 to $38.00 and gave the company a "market outperform" rating in a research report on Thursday, July 31st. Finally, Barrington Research reissued an "outperform" rating and issued a $38.00 price objective on shares of Option Care Health in a report on Tuesday, September 23rd. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, Option Care Health has a consensus rating of "Moderate Buy" and an average price target of $35.11.

Option Care Health Stock Performance

Shares of OPCH opened at $27.24 on Thursday. Option Care Health has a one year low of $21.39 and a one year high of $35.53. The company has a 50-day simple moving average of $28.44 and a two-hundred day simple moving average of $30.93. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.52 and a quick ratio of 1.00. The firm has a market capitalization of $4.42 billion, a PE ratio of 21.79, a price-to-earnings-growth ratio of 1.68 and a beta of 0.88.

Option Care Health (NASDAQ:OPCH - Get Free Report) last released its earnings results on Wednesday, July 30th. The company reported $0.41 earnings per share for the quarter, topping analysts' consensus estimates of $0.40 by $0.01. Option Care Health had a net margin of 3.93% and a return on equity of 17.53%. The firm had revenue of $1.42 billion for the quarter, compared to the consensus estimate of $1.35 billion. During the same period in the prior year, the firm earned $0.30 EPS. The company's revenue was up 15.4% compared to the same quarter last year. Option Care Health has set its FY 2025 guidance at 1.650-1.720 EPS. On average, analysts anticipate that Option Care Health will post 1.22 EPS for the current fiscal year.

Insider Transactions at Option Care Health

In other Option Care Health news, Director Norman L. Wright acquired 3,411 shares of the company's stock in a transaction on Tuesday, September 9th. The stock was acquired at an average cost of $29.31 per share, with a total value of $99,976.41. Following the purchase, the director directly owned 15,501 shares of the company's stock, valued at approximately $454,334.31. This represents a 28.21% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Harry M. Jansen Kraemer, Jr. acquired 36,000 shares of the stock in a transaction dated Wednesday, August 20th. The stock was bought at an average cost of $27.15 per share, with a total value of $977,400.00. Following the completion of the purchase, the director directly owned 375,390 shares in the company, valued at approximately $10,191,838.50. The trade was a 10.61% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought 59,411 shares of company stock valued at $1,627,576 in the last ninety days. Corporate insiders own 0.64% of the company's stock.

Institutional Investors Weigh In On Option Care Health

A number of institutional investors have recently added to or reduced their stakes in OPCH. Durable Capital Partners LP grew its position in shares of Option Care Health by 134.2% in the 2nd quarter. Durable Capital Partners LP now owns 8,237,577 shares of the company's stock worth $267,557,000 after buying an additional 4,720,988 shares during the last quarter. Fuller & Thaler Asset Management Inc. increased its position in Option Care Health by 30.8% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 4,204,481 shares of the company's stock valued at $146,947,000 after buying an additional 989,048 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its stake in Option Care Health by 109.0% in the second quarter. Arrowstreet Capital Limited Partnership now owns 3,410,394 shares of the company's stock valued at $110,770,000 after buying an additional 1,778,279 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Option Care Health by 4.0% in the first quarter. Charles Schwab Investment Management Inc. now owns 2,609,705 shares of the company's stock worth $91,209,000 after acquiring an additional 99,574 shares in the last quarter. Finally, Norges Bank acquired a new stake in Option Care Health in the second quarter worth about $69,932,000. Institutional investors own 98.05% of the company's stock.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.